CB-03-01

CB-03-01, a new chemical entity patented by Cosmo, is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.

The objective is to create a product for topical application to treat acne, male pattern baldness, and seborrhoea that does not have the side effects of products currently being taken in tablet form.

The company has completed the phase I clinical trials, and completed the phase II proof of concept trial for the treatment of acne vulgaris. The results show clinically and statistically superiority to placebo on all scores, clinically better than Retin^® A cream, and very well tolerated.

Cosmo's patents expire in the year 2022 and 2028.